CA2636533A1 - Use of tpp ii inhibitors in combination with gamma-irradiation for the treatment of cancer - Google Patents

Use of tpp ii inhibitors in combination with gamma-irradiation for the treatment of cancer Download PDF

Info

Publication number
CA2636533A1
CA2636533A1 CA002636533A CA2636533A CA2636533A1 CA 2636533 A1 CA2636533 A1 CA 2636533A1 CA 002636533 A CA002636533 A CA 002636533A CA 2636533 A CA2636533 A CA 2636533A CA 2636533 A1 CA2636533 A1 CA 2636533A1
Authority
CA
Canada
Prior art keywords
compound
alkyl
gamma
phenyl
unbranched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002636533A
Other languages
English (en)
French (fr)
Inventor
Rickard Glas
Hong Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ONCOREG AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2636533A1 publication Critical patent/CA2636533A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002636533A 2006-01-13 2007-01-15 Use of tpp ii inhibitors in combination with gamma-irradiation for the treatment of cancer Abandoned CA2636533A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75908806P 2006-01-13 2006-01-13
US60/759,088 2006-01-13
PCT/EP2007/050363 WO2007080194A2 (en) 2006-01-13 2007-01-15 Use of tpp ii inhibitors in combination with gamma-irradiation for the treatment of cancer

Publications (1)

Publication Number Publication Date
CA2636533A1 true CA2636533A1 (en) 2007-07-19

Family

ID=36609604

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002636533A Abandoned CA2636533A1 (en) 2006-01-13 2007-01-15 Use of tpp ii inhibitors in combination with gamma-irradiation for the treatment of cancer

Country Status (8)

Country Link
US (2) US20100168038A1 (cg-RX-API-DMAC10.html)
EP (2) EP1971357A2 (cg-RX-API-DMAC10.html)
JP (2) JP2009523156A (cg-RX-API-DMAC10.html)
KR (1) KR20080085035A (cg-RX-API-DMAC10.html)
CN (1) CN101370509A (cg-RX-API-DMAC10.html)
AU (1) AU2007204314A1 (cg-RX-API-DMAC10.html)
CA (1) CA2636533A1 (cg-RX-API-DMAC10.html)
WO (2) WO2007088099A2 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009000296A2 (en) * 2007-06-25 2008-12-31 Oncoreg Ab Tpp ii inhibitors for use in the treatment of autoimmune and inflammatory diseases and transplant rejection
WO2009000297A1 (en) * 2007-06-25 2008-12-31 Oncoreg Ab Tpp ii inhibitors for use in combination with chemotherapy for the treatment of cancer
US8779002B2 (en) * 2007-10-15 2014-07-15 Salk Institute For Biological Studies Methods for treating a variety of diseases and conditions, and compounds useful therefor
MY159958A (en) * 2009-12-18 2017-02-15 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
WO2011159685A2 (en) * 2010-06-16 2011-12-22 The Regents Of The University Of Michigan Inhibition of wdr5 interaction with its binding partners and therapeutic methods
CA2822442C (en) * 2010-12-22 2021-03-16 The Salk Institute For Biological Studies Cyclic crf antagonist peptides
WO2015040235A1 (en) 2013-09-23 2015-03-26 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Anti-inflammatory tripeptides
JP2017525684A (ja) * 2014-07-24 2017-09-07 ノーレックス インコーポレイテッド N−メチル−d−アスパラギン酸受容体モジュレーターならびにその製造方法及び使用方法
CN111603560A (zh) * 2020-06-22 2020-09-01 泉州台商投资区秋鑫茶业有限公司 茶叶γ-氨基丁酸在肿瘤放射治疗上的应用
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627035A (en) * 1990-08-22 1997-05-06 Syntello Vaccine Development Ab Peptides that block human immunodeficiency virus and methods of use thereof
ATE173934T1 (de) * 1990-08-22 1998-12-15 Anders Vahlne Peptide, die infektionen mit menschlichem immunschwächevirus hemmen und deren anwendungsweisen
JP3943332B2 (ja) * 1997-12-23 2007-07-11 アンスティテュ ナシオナル ドゥ ラ サントゥ エ ドゥ ラ ルシェルシェ メディカル(イーエヌエスエーエールエム) トリペプチジルペプチダーゼインヒビター
US6258932B1 (en) * 1999-08-09 2001-07-10 Tripep Ab Peptides that block viral infectivity and methods of use thereof
DE10105039A1 (de) * 2001-02-05 2002-08-08 Tell Pharm Ag Hergiswil Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten
EP1436317A1 (en) * 2001-09-19 2004-07-14 Tripep Ab Molecules that block viral infectivity and methods of use thereof
US20040097422A1 (en) * 2002-06-14 2004-05-20 Karl Munger Methods of use for tripeptidyl peptidase II inhibitors as anticancer agents
EP1716247A1 (en) * 2004-01-31 2006-11-02 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with tripeptidyl-peptidase 2 (tpp2)

Also Published As

Publication number Publication date
AU2007204314A1 (en) 2007-07-19
US20100168038A1 (en) 2010-07-01
WO2007080194A3 (en) 2008-02-14
KR20080085035A (ko) 2008-09-22
JP2009523157A (ja) 2009-06-18
WO2007080194A2 (en) 2007-07-19
EP1971357A2 (en) 2008-09-24
CN101370509A (zh) 2009-02-18
WO2007088099A2 (en) 2007-08-09
WO2007088099A3 (en) 2007-11-08
US20090227521A1 (en) 2009-09-10
JP2009523156A (ja) 2009-06-18
EP2160196A2 (en) 2010-03-10

Similar Documents

Publication Publication Date Title
US20100168038A1 (en) Use of compounds in combination with gamma-irradiation for the treatment of cancer
CN102245632B (zh) Muc-1胞质结构域肽作为癌症的抑制剂
US20230087443A1 (en) Enhancement of cd47 blockade therapy by proteasome inhibitors
ES2368864T3 (es) Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes.
EA007396B1 (ru) Иммуноконъюгаты для лечения опухолей
WO2012051207A2 (en) FRAGMENT OF SECRETED HEAT SHOCK PROTEIN-90ALPHA (Hsup90ALPHA) AS VACCINES OR EPITOPE FOR MONOCLONAL ANTIBODY DRUGS OR TARGET FOR SMALL MOLECULE DRUGS AGAINST A RANGE OF SOLID HUMAN TUMORS
Huang et al. Cytochalasin D, a tropical fungal metabolite, inhibits CT26 tumor growth and angiogenesis
Lee et al. Zfra activates memory Hyal-2+ CD3− CD19− spleen cells to block cancer growth, stemness, and metastasis in vivo
EP4408471A2 (en) Borylated di-peptide amino acid compositions for use in boron neutron capture therapy and methods thereof
WO2009000297A1 (en) Tpp ii inhibitors for use in combination with chemotherapy for the treatment of cancer
AU2005295915A1 (en) Anticancer compounds and methods
CA2691415A1 (en) Tpp ii inhibitors for use in the treatment of autoimmune and inflammatory diseases and transplant rejection
WO2013009165A1 (en) A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine
WO2023133442A2 (en) Protac molecules targeting foxp3 and uses thereof
EP2670416B1 (en) A novel high affinity bivalent helically constrained peptide against cancer
조영석 Caspase-3 activated prodrugs for biomarker based targeted chemotherapy in TNBC
Gokbayrak Atay et al. The Importance of Apoptosis in Cancer Development and Treatment
WO2003095484A2 (en) Polypeptides increasing p53 expression
Santin et al. Overexpression of Claudin-3 and Claudin-4 Receptors in Uterine Serous Papillary Carcinoma
HK1229242A1 (en) Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer
HK1229242B (en) Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer

Legal Events

Date Code Title Description
FZDE Discontinued